The first Phase III and second Phase III trials will be multi-centre, randomised, assessor-blind, active-comparator studies to determine the efficacy, safety and tolerability of orally administered Zintrodiazine
_256_384.jpg)
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
New appointments bring diagnostics and medtech expertise to strengthen healthcare delivery and policy engagement
New model focuses on continuity of care, combining therapy, routine and social engagement to support long-term recovery
VESCOP, ENTOD Pharmaceuticals, and APTI-MSB host the event to bridge lab-to-clinic gap in eye care
The summit brought together over 150 doctors, researchers, and practitioners worldwide
AI-powered platform uses real-time emotion scanning and personalised interventions to make emotional wellness measurable and actionable
Multi-stakeholder initiative highlights inclusive sports pathways, honours neurodivergent athletes, and calls for systemic reforms
Profitability came under strain. Gross profit fell to EUR 246m, with margins narrowing to 23.7% as negative product mix—particularly in Asia Pacific—weighed on performance
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
Subscribe To Our Newsletter & Stay Updated
